Evaluation of the effectiveness and safety of bianshi moxibustion infrared dry eye therapeutic instrument in the treatment of meibomian gland dysfunction

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR1900002769

Enrollment

Unknown

Registered

2019-11-22

Start date

2019-12-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

meibomian gland dysfunction

Interventions

Group 4:Conventional infrared therapy

Group 1:MGD was treated with bian-stone moxibustion infrared dry eye therapeutic instrument (twice a day, 30min each time).

Group 3:MGD was treated with bian-stone moxibustion infrared dry eye therapeutic instrument (three times a day, 20min each time)

Group 2:MGD was treated with bian-stone moxibustion infrared dry eye therapeutic instrument (twice a day, 20min each time).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18~80 years old; 2. Diagnostic criteria of dry eye: (1) Ocular symptoms: 1) Feeling dry eye every day for more than 3 months; 2) Repeated foreign body sensation; 3) Using artificial tears more than 3 times one day; (2) Ocular signs: 1) Schirmer I test (ST-I)(no anesthesia) =4 (according to van Bijsterveld scoring standard); The diagnosis of dry eye requires at least one symptom and one sign. 3. Diagnostic criteria of meibomian gland dysfunction (1) Absence of meibomian glands; (2) Abnormal of eyelid margin and meibomian gland; (3) Changes in the quantity and quality of meibomian secretion; MGD could be diagnosed with any of these signs in combination with dry eye symptoms.

Exclusion criteria

Exclusion criteria: (1) Caused by systemic diseases (pain, fever, cough) or other external environmental factors. (2) Complicated with other eye diseases (glaucoma, cataract, retinal detachment, etc.) or undergone eye surgery. (3) Systemic connective tissue disease or severe autoimmune diseases (4) Patients with central nervous system disease or craniocerebral surgery. (5) Patients with severe diseases of heart, lung, liver, kidney or blood system. (6) Patients who suspect or have a history of alcohol or drug abuse or mental illness. (7) Allergic constitution. (8) Pregnant or lactating women. (9) Patients who have taken medication for dry eye in the last 2 weeks. (10) Patients who have participated in other clinical trials within the last 1 month or have accepted the randomized group of this clinical trial. (11) The investigator considers that the participants are not suitable for this clinical trial.

Design outcomes

Primary

Measure	Time frame
Eyelid margin score;Corneal fluorescein staining score;Ocular Surface Disease Index;Tear break up time;Schirmer I test;Tear meniscus height;Meibomian gland score;	—

Countries

China

Contacts

Public ContactXuemin Li

13911254862@163.com+86 13911254862

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026